Material on the National Drug Strategy site is being reviewed following the federal election on 24 November 2007. This revised web site will reflect the new government's policies, programs and priorities for the health and ageing portfolio.

National Drug Strategy
National Drug Strategy

Management of Patients with Psychostimulant Use Problems. Guidelines for General Practitioners

Print page  Decrease text size  Increase text size

The aim of the guidelines is to assist general practitioners to identify patients who may be using psychostimulants; engage psychostimulant users in treatment; and identify and manage a range of adverse consequences of stimulant use including acute toxicity.

Published by Commonwealth Department of Health and Ageing
2007

The guidelines were originally published in 2004 and were reviewed and updated in 2007.

These guidelines have been developed to coincide with the update of the National Drug Strategy Monograph No 51, Second Edition, Models of intervention and care for psychostimulant users. Their purpose is to provide guidelines for general practitioners throughout Australia to effectively and safely manage individuals who are experiencing problems related to the use of psychostimulants, including psychostimulant and serotonin toxicity.

The aim of the guidelines is to assist general practitioners to identify patients who may be using psychostimulants; engage psychostimulant users in treatment; and identify and manage a range of adverse consequences of stimulant use including acute toxicity.

Management of Patients with Psychostimulant Use Problems. Guidelines for General Practitioners (PDF 138 KB)

Page currency, Latest update: 2007

If you are having difficulty downloading the PDF document(s) please email phd.webmaster@health.gov.au and we will arrange for an alternative format or a copy to be sent to you.

Get Acrobat ReaderTo view PDF (Portable Document Format) documents, you will need to have a PDF reader installed on your computer. The Adobe Acrobat Reader is available free of charge from Adobe's website.